Literature DB >> 18998303

Study of adverse drug reactions caused by first line anti-tubercular drugs used in directly observed treatment, short course (DOTS) therapy in Western Nepal, Pokhara.

Anupa Khadka Chhetri1, Anupa Khatri Chhetri, Archana Saha, Sharat Chandra Verma, Subish Palaian, Pranaya Mishra, Pathiyil Ravi Shankar.   

Abstract

OBJECTIVE: To study the Adverse Drug Reactions occurring during DOTS therapy and to assess their causality, severity and predisposing factors.
METHOD: Patients undergoing DOTS treatment during the 5 month study period (20th January to 20th June, 2005) at the Regional Tuberculosis Center (RTC) in Pokhara, Western Nepal were studied. Patients and/or patient party were interviewed to detect occurrence of any ADRs during their visit to the DOTS center. Causality and severity assessment were carried out as per the 'Naranjo scale' and 'modified Hartwig and Siegel scale' respectively. Statistical analysis (Chi square test) was done to determine the predisposing factors.
RESULTS: Totally 137 patients were studied among whom 54.74% (n=75) reported occurrence of ADRs. Total 29.33% of ADRs were reported by the age group 21- 30 years. Nearly half (49.33%) of the ADRs were reported by men and 33.33% were reported by the ethnic group of 'Gurungs'. Half (49.33%) of the patients were illiterate and 70.67% of the ADRs were classified as ADRs 'possibly' due to the suspected drugs and 93.33% were classified as 'mild (level 1)'. Isoniazid accounted for 49.3% of the ADRs. The most commonly reported ADR was tingling and burning sensation in hands and feet experienced by 32 (11.03%) patients.
CONCLUSION: Occurrence of ADRs from antitubercular drugs was high in the population of Western Nepal. Further studies encompassing a wider population and covering different regions of Nepal are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18998303

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  15 in total

1.  Comparison of Directly Observed Treatment Short Course (DOTS) with Self-Administered Therapy in Pulmonary Tuberculosis in Udupi District of Southern India.

Authors:  Amrita Parida; K L Bairy; Bharti Chogtu; Rahul Magazine; Sudha Vidyasagar
Journal:  J Clin Diagn Res       Date:  2014-08-20

2.  Rifampicin-Induced Concomitant Renal Injury and Hepatitis.

Authors:  Bharti Chogtu; Vyshak Uddur Surendra; Rahul Magazine; Preetam Rajgopal Acharya; Devesh Bhaskar Yerrapragada
Journal:  J Clin Diagn Res       Date:  2016-09-01

3.  Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis.

Authors:  L Aït Moussa; O El Bouazzi; S Serragui; D Soussi Tanani; A Soulaymani; R Soulaymani
Journal:  Ther Adv Drug Saf       Date:  2016-09-07

4.  Defensive role of Nigella sativa against antituberculosis drugs induced renal toxicity.

Authors:  Amita Jaswal; Samta Sharma; Chhavi Uthra; Deepa Yadav; Sadhana Shrivastava; Sangeeta Shukla
Journal:  Toxicol Res (Camb)       Date:  2022-04-04       Impact factor: 2.680

5.  Adverse Drug Reaction Profile in Patients on Anti-tubercular Treatment Alone and in Combination with Highly Active Antiretroviral Therapy.

Authors:  Shamiya Sadiq; Vijay Khajuria; Vishal R Tandon; Annil Mahajan; Jang B Singh
Journal:  J Clin Diagn Res       Date:  2015-10-01

6.  Quality of sleep among patients diagnosed with tuberculosis-a cross-sectional study.

Authors:  Jeffrey Pradeep Raj; Naveen Ramesh
Journal:  Sleep Breath       Date:  2020-11-10       Impact factor: 2.816

7.  Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco.

Authors:  Mariam El Hamdouni; Samir Ahid; Jamal Eddine Bourkadi; Jouda Benamor; Mohammed Hassar; Yahia Cherrah
Journal:  Infection       Date:  2019-06-04       Impact factor: 7.455

8.  Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study.

Authors:  Xiaozhen Lv; Shaowen Tang; Yinyin Xia; Xiaomeng Wang; Yanli Yuan; Daiyu Hu; Feiying Liu; Shanshan Wu; Yuan Zhang; Zhirong Yang; Dehua Tu; Yixin Chen; Peiyuan Deng; Yu Ma; Ru Chen; Siyan Zhan
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

9.  Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection.

Authors:  Evans Sagwa; Nunurai Ruswa; Jean Paul Musasa; Aukje K Mantel-Teeuwisse
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.228

10.  Revised National Tuberculosis Control Program regimens with and without directly observed treatment, short-course: A comparative study of therapeutic cure rate and adverse reactions.

Authors:  Rengaraj Sivaraj; Sivaraj Umarani; Subramani Parasuraman; Pyapti Muralidhar
Journal:  Perspect Clin Res       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.